Table 4.
Hazard Ratios by HPV-16 E6/E7 baseline status and change in OD ratio at last follow-up
| Outcome/Antibody Status | HPV-16 E6 | HPV-16 E7 | HPV-16 E6 and/or E7 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | HR (95% CI)1 | p-value2 | n (%) | HR (95% CI)1 | p-value2 | n (%) | HR (95% CI)1 | p-value2 | |
| Overall Deaths | 0.01 | 0.04 | 0.01 | ||||||
| Negative | 353 (40.2) | 4.6 (1.4-15.3) | 344 (38.2) | 3.0 (1.03-8.5) | 344 (41.0) | 3.8 (1.3-11.0) | |||
| Positive | 3 (13.6) | 1.0 | 4 (20.0) | 1.0 | 4 (15.8) | 1.0 | |||
| No OD decrease | 0 | 0 | 0 | ||||||
| OD Decrease | 35 | 45 | 45 | ||||||
| Disease Specific Deaths | 0.017 | 0.07 | 0.04 | ||||||
| Negative | 196 (24.4) | NE3 | 188 (22.5) | 6.4 (0.8-48.7) | 188 (24.3) | 8.4 (1.1-63.3) | |||
| Positive | 0 (0.0) | 1.0 | 1 (5.6) | 1.0 | 1 (4.2) | 1.0 | |||
| No OD decrease | 0 | 0 | 0 | ||||||
| OD Decrease | 0 | 15 | 15 | ||||||
| Recurrence | 0.35 | 0.36 | 0.90 | ||||||
| Negative | 178 (21.5) | 2.1 (0.4-9.7) | 174 (21.0) | 2.0 (0.4-9.4) | 159 (20.0) | 1.1 (0.3-3.5) | |||
| Positive | 2 (9.1) | 1.0 | 2 (10.0) | 1.0 | 4 (15.4) | 1.0 | |||
| No OD decrease | 15 | 0 | 25 | ||||||
| OD Decrease | 1 | 210 | 210 | ||||||
1Adjusted for continuous age and stage; 2Adjusted p-value from Cox Regression models; 3Tumor status: 3 HPV-16, 1 HPV-33, 27 HPV-; 4Tumor status: 2 HPV-16, 1 HPV-33, 27 HPV-; 5Tumor status: all HPV-16; 6Tumor status: 2 HPV-16, 18 HPV-; 7Not estimable, Kaplan-Meier log-rank p = 0.01; 8Tumor status: 1 HPV-16, 1 HPV-33, 14 HPV-; 9Tumor status: 1 HPV-33, 13 HPV-; 10Tumor status: 1 HPV-16, 1 HPV-.